Tumor Treating Fields Plus Temozolomide Maintenance After Radiochemotherapy in Chinese Grade 4 Gliomas: Efficacy and Predictive Biomarkers

Clicks: 1
ID: 322445
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #80 of 103 articles by views in Neuro-Oncology Advances

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objective The EF-14 trial established the survival benefit of adding TTFields to maintenance temozolomide (TMZ) following standard radiochemotherapy in glioblastoma (GBM). Whether this benefit is reproducible in Chinese grade 4 glioma patients in real-world practice—and what biomarkers predict response—remains unknown. This study evaluates TTFields efficacy in a Chinese cohort and explores predictive biomarkers. Methods We conducted a retrospective analysis of Chinese patients with grade 4 gliomas who underwent surgery and postoperative radiochemotherapy, followed by maintenance TMZ with or without TTFields treatment at Tongji Hospital, Huazhong University of Science and Technology, between November 2019 and November 2024. The Kaplan–Meier method was used to plot survival curves for overall survival (OS) and progression-free survival (PFS), and the log-rank test was applied for group comparisons. Univariate Cox proportional hazards regression analysis was performed to identify factors associated with PFS and OS. Subgroup analyses were conducted, and results were visualized using forest plots. Results A comprehensive dataset of 64 postoperative grade 4 glioma patient records was compiled in the study. Among them, 22 patients (34.4%) were administered TTFields treatment. The TTFields-treated group demonstrated a significant improvement in OS compared to the non-TTFields-treated group (median OS: 15 months vs. 11 months, p = 0.047). Univariate Cox analysis identified the chromosome 7 gain and chromosome 10 loss as a significant risk factor for shortened PFS (HR = 2.294; 95% CI, 1.268–4.150; p = 0.006) and OS (HR = 2.831; 95% CI, 1.507–5.316; p = 0.001). Subgroup analysis revealed that TTFields treatment resulted in better PFS for O6-methylguanine DNA methyltranferase (MGMT)-unmethylated patients [HR (95% CI) = 2.269 (1.066–4.83), p = 0.033], and isocitrate dehydrogenase (IDH) wild-type patients [HR (95% CI) = 2.101 (1.029–4.291), p = 0.042]. In terms of OS, TTFields treatment was associated with improved OS in patients with multiple surgical sites [HR (95% CI) = 4.148 (1.073–16.033), p = 0.039], MGMT-unmethylated patients [HR (95% CI) = 2.421 (1.113–5.263), p = 0.026], IDH wild-type patients [HR (95% CI) = 2.169 (1.039–4.526), p = 0.039], and those with Ki-67 < 20% [HR (95% CI) = 9.398 (1.122–78.75), p = 0.039]. Conclusion In this retrospective cohort of Chinese patients with grade 4 glioma, adding TTFields to maintenance TMZ therapy following standard postoperative radiochemotherapy was associated with improved OS compared with maintenance TMZ alone, whereas the improvement in PFS did not reach statistical significance. Chromosome 7 gain and chromosome 10 loss was identified as a significant risk factor for shorter PFS and OS. Exploratory subgroup analyses suggested greater potential benefit in patients with MGMT-unmethylated tumors, IDH wild-type tumors, multiple surgical sites, or Ki-67 < 20%. Given the small sample size, retrospective non-randomized design, and wide confidence intervals in some subgroup estimates, these findings should be interpreted cautiously and validated in larger prospective multicenter studies.
Reference Key
openalex_W7170188336 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Wenjun Zhu, Jie Rao, Guangyuan Hu, Runkun Wang, Xiaoxiao Luo, Qi Li
Journal Neuro-Oncology Advances
Year 2026
DOI
10.1093/noajnl/vdag194
URL
https://doi.org/10.1093/noajnl/vdag194
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.